Only 1.6% (4/250) of newly diagnosed pulmonary TB patients had combined drug resistance to INH+STM, 1.2% (3/250) to INH+ETB, and 0.4% (1/250) to STM+EMB. This evidence concerns the gene EDNRB and pulmonary tuberculosis.